PET scan tracer study for ovarian or related cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This early study tests a radioactive tracer (given as an injection) and tracks how it moves through the body using PET/CT scans. It may help doctors better understand how this tracer behaves in cancers of the ovaries, fallopian tubes, or the lining of the abdomen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer
- You must have at least one visible spot (lesion) at least 1 cm on routine scans
- If you can become pregnant, you cannot be pregnant or breastfeeding during screening
- You must be able to safely tolerate the imaging procedures for this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new PET/CT imaging tracer to see how well it can detect breast cancer spots in the body. It may help doctors learn where breast cancer is and how imaging could work better in the future.
This early-phase study uses PET/CT scans to see how well a new radioactive tracer (a tiny dose of a special material) highlights solid tumors in the body. It may help researchers learn whether this tracer can better find and track tumor spots seen on standard scans.
This pilot study uses a special PET/CT scan (with a radioactive tracer) to help doctors better “stage” high-grade epithelial ovarian cancer—especially when it’s advanced. The goal is to see whether the scan can improve planning for treatment like surgery or chemotherapy first.
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
This trial tests a special PET/CT scan using a new tracer (68Ga-FAPI) to help show tumors in the pancreas, bile ducts, stomach, or certain ovarian cancers. It may help doctors better see where cancer is in preparation for surgery or biopsy.
This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.
Hear when a new Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.